AHP TO EXPAND LODINE LINE IN 1996; DURACT, NAPRELAN LAUNCHES WILL BUILD NSAID MARKET PRESENCE: NEUMEGA (INTERLEUKIN-11) PLA SLATED FOR MID-1997
Executive Summary
Wyeth-Ayerst is waiting for final clearance of a new strength and a new indication for the nonsteroidal anti-inflammatory drug Lodine to reinvigorate growth for the product in 1996.